ModernaTX, Inc is recruiting patients for the clinical trial of Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors.
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab.
The population that can be enrolled have histologically confirmed locally advanced or metastatic cancer (cutaneous melanoma, non-small-cell lung carcinoma (NSCLC), non-muscle invasive bladder cancer, head and neck squamous cell carcinoma, Microsatellite stable colorectal cancer (MSS CRC), basal cell carcinoma, or triple negative breast cancer) with measurable disease as determined by RECIST v1.1. They must have received, and then progressed, relapsed, or been intolerant to, or ineligible for, at least 1 standard treatment regimen in the advanced or metastatic setting. For more complete details please vesit: https://ichgcp.net/clinical-trials-registry/NCT05533697.
The indicative completion of the clinical trial will be expected in December 8, 2027, and the study sites are located at the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California; University of Colorado Cancer Center, Aurora; Orlando Health UF Health Cancer Center, Florida; The University of Chicago Medicine, Chicago, Illinois; Massachusetts General Hospital, Boston, Massachusetts; Henry Ford Hospital, Detroit, Michigan; John Theurer Cancer Center, Hackensack, New Jersey; Westchester Medical Center, Hawthorne, New York; Carolina BioOncology Institute, Huntersville, North Carolina; Sara Cannon Research Institute Tennessee, Nashville, Tennessee.